Specialty School of Pediatrics-Alma Mater Studiorum, University of Bologna, 40138 Bologna, Italy.
Department of Pediatric Rheumatology, Meyer Children University Hospital, 50139 Florence, Italy.
Nutrients. 2021 Nov 10;13(11):4005. doi: 10.3390/nu13114005.
The efficacy of diet and its influence on gut microbiome composition has been largely demonstrated in inflammatory bowel disease (IBD). Little is known about its potential in the management of extraintestinal manifestations. We report a successful application of Crohn disease exclusion diet (CDED) in association with infliximab and methotrexate, as salvage therapy in a child affected by chronic recurrent multifocal osteomyelitis (CRMO) and Crohn disease (CD) resistant to optimized therapy. Both intestinal and bone symptoms remitted after the application of CDED. Diet may have acted on common microbic inciting agents that trigger both intestinal and bone inflammation, supporting the role of microbiota in the pathogenesis of IBD-associated extraintestinal manifestations. Our experience suggests the potential benefit of CDED in association with combined therapy in resistant patients affected by CD and extraintestinal manifestations.
饮食的疗效及其对肠道微生物组成的影响在炎症性肠病 (IBD) 中已得到广泛证实。然而,关于其在治疗肠外表现方面的潜在作用,我们知之甚少。我们报告了一例克罗恩病排除饮食(CDED)在英夫利昔单抗和甲氨蝶呤联合应用中的成功应用,作为对优化治疗耐药的慢性复发性多灶性骨髓炎(CRMO)和克罗恩病(CD)患儿的挽救治疗。在应用 CDED 后,肠道和骨骼症状均得到缓解。饮食可能作用于共同的微生物引发剂,引发肠道和骨骼炎症,支持微生物群在 IBD 相关肠外表现发病机制中的作用。我们的经验表明,在耐药患者中,CDED 联合治疗可能对 CD 和肠外表现有益。